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Neuromuscular diseases are characterized by degeneration of motorneurons and atrophy 
of the muscles which they innervate.  At the cellular level, neuropathological markers include a 
decrease in cell body size, dendritic atrophy, loss of synaptic input, and vacuolation.  These 
markers are precursors to eventual apoptotic death of neurons.  Although the progressive 
pathological hallmarks of most neuromuscular diseases are well-characterized, their origins, in 
many cases, remain largely unknown.  One possible trigger of pathology associated with 
neuromuscular diseases is a loss or reduction of brain-derived neurotrophic factor (BDNF) in the 
motor unit.  BDNF is a neurotrophic protein synthesized by both motorneurons and muscles, and 
promotes cell survival, growth and differentiation.  Preliminary data indicate that mice lacking 
(or with reduced) BDNF synthesized by skeletal muscles display neuromuscular deficits in 
adulthood, including decreased grip strength, decreased stride length, and increased clasping 
behavior.  We hypothesized that absent or reduced BDNF synthesized by muscles will lead to 
many of the same neuropathological markers present in common neuromuscular diseases.  To 
address this possibility, we used a Cre-recombinase/LoxP gene knockout system to generate 
experimental mice missing one or both alleles of the BDNF gene only in skeletal muscle.  To 
assess transgenic mice for progressive neuropathological markers, Nissl staining, 
immunocytochemistry, and light and confocal microscopy were utilized.  These techniques 
allowed us to identify and characterize potential pathological changes in motorneurons and 
associated.  This thesis will focus on progressive pathology associated with spinal motorneurons.  
Motorneurons of experimental and control mice were enumerated and analyzed for BDNF 
expression, dendritic atrophy, loss of synaptic input, and the appearance of cellular vacuolation.  
Analysis was carried out using two age groups (30 d and 120 d) to determine whether the 
appearance of potential cellular pathology was progressive.  Results indicate that reduced or 
absent muscle-synthesized BDNF leads to decreased cell body size, altered amounts of BDNF 
protein present in motorneurons, and decreased length and diameter of motorneuron dendrites.  
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CHAPTER ONE: INTRODUCTION & LITERATURE REVIEW 
 
Neurotrophins, also known as neurotrophic factors, are a family of diffusible proteins that 
generally promote the survival, growth, and differentiation of neurons [1].  The neurotrophin 
family includes nerve growth factor (NGF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), 
neurotrophin-5 (NT-5) and brain-derived neurotrophic factor (BDNF), among others.  
Neurotrophic factors are important for the growth of developing neurons and the maintenance of 
mature neurons throughout the central and peripheral nervous systems [1-3].  At times during 
development, they can play an opposite role, and function to prune unwanted neurons from the 
nervous system [4-7].  Neurotrophins function as anterograde, retrograde, autocrine, and 
paracrine signaling molecules.  Anterograde transport (cell body to axon terminal) and retrograde 
transport (axon terminal to cell body) are neuron-specific systems for transporting cargo.  The 
mechanisms of these systems are described in detail later in this introduction.  As such, they are 
released from both presynaptic terminals and postsynaptic membranes and bind to receptors 
expressed by target cells (anterograde, retrograde, paracrine) or the cell that released them 
(autocrine).  NGF, NT 3-5, and BDNF bind to two families of receptors – (1) p75
NTR
, which 
binds all five neurotrophins, and (2) the tyrosine kinase (Trk) receptors TrkA, TrkB, and TrkC, 
which have differing binding affinities for each neurotrophin [8].  BDNF, the focus of this 
project, preferentially binds to the TrkB receptor. 
Due to their involvement in regulating cell survival and apoptosis, neurotrophic factors 
have been well-characterized in models of nervous system development.  More recently, their 
roles in the postnatal and adult maintenance of functional neural morphology and synaptic 
plasticity have been described [9-13].  In particular, BDNF has been shown to play a role in 
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synaptic plasticity and memory formation in both the hippocampus and the amygdala [12, 14-
17].  Fear-conditioning in rats leads to upregulation of BDNF, which aids in the consolidation of 
fear memory in the amygdala [14, 15].  Application of antagonists for the TrkB receptor 
impaired consolidation of fear learning and extinction retention [15-17].  BDNF also modulates 
long-term potentiation (LTP) in the adult hippocampus.  Within the hippocampus, BDNF is 
stored in dendritic processes and is released after high frequency stimulation (HFS) [18].  The 
TrkB receptor is located both pre- and postsynaptically [19].  This distribution indicates that 
BDNF can initiate a signaling cascade in both an anterograde and a retrograde manner.  A review 
by Bramham and Messodusi (2005) describes the permissive and instructive roles played by 
BDNF in hippocampal synaptic plasticity.  The permissive role refers to maintenance of the 
synapse by basal levels of BDNF (not released due to HFS).  The instructive refers to the action 
of HFS-evoked BDNF release.  In this situation, BDNF activates pathways leading to local 
enhanced translation of synaptic-associated mRNA stored in dendrites and is implicated in the 
process of long-term potentiation (LTP) in memory formation [20-23].  Additionally, BDNF 
signaling leads to enhanced actin polymerization in dendritic spines, thus increasing the number 
and size of synapses as a result of HFS.  This actin polymerization was diminished by a BDNF 
antagonist [24].  In addition to the neurotrophin’s role in hippocampal and amygdalar function, 
the distribution of BDNF and its receptor is observed throughout the CNS, including the spinal 
cord, thus suggesting a widespread role for the protein [46]. 
As indicated, BDNF and TrkB proteins are expressed by multiple neural phenotypes in 
the telencephalon, diencephalon, midbrain, brainstem, and spinal cord.  In addition, these 
proteins can be found in the peripheral nervous system, as well as many other tissues, including 
liver, kidneys, retina, prostate, and skeletal muscle [25-28].  Recent research suggests that it is 
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retrograde signaling of the neurotrophins (from postsynaptic cell to presynaptic cell) in particular 
that plays a significant role in the maintenance, growth, and synaptic plasticity of the innervating 
neuron [8, 29-31].  This is of particular interest in research involving the spinal motor units, as 
skeletal muscle has been shown to be a significant source of neurotrophin synthesis during 
development [1-3, 32].  Recent studies reveal BDNF as one of the key players in a trophic 
support system that maintains the motorneurons and muscles of a motor unit in adulthood [33-
35].  Neurotrophic-dependent maintenance of an adult neuromuscular system is typified by the 
well-described spinal nucleus of the bulbocavernosus (SNB) in rodents.  The SNB is a sexually 
dimorphic nucleus of the lumbar spinal cord that is significantly larger in males, as it innervates 
the bulbocavernosus and levator ani muscles of the penis, as well as the external anal sphincter.  
Treatment of severed SNB axons with BDNF can prevent both axotomy- or castration-induced 
declines in soma size and expression of androgen receptor (AR) of SNB motorneurons [36-38].  
Additionally, treatment of axotomized male rats with BDNF and testosterone will ameliorate 
axotomy-associated declines in dendritic arborizations [36, 39].  These studies show that 
androgens upregulate TrkB receptors expressed by SNB motorneurons which are believed to 
retrogradely transport muscle-synthesized BDNF to the cell body.  A group of researchers also 
recently described the synergistic, trophic effects of androgens and BDNF in the quadriceps 
muscles and their innervating motorneurons – a non-sexually dimorphic neuromuscular system.  
In their study, castration reduced immunolabeling of BDNF protein in quadriceps muscles and 
motorneurons, and treatment with testosterone ameliorated this deficit [40, 41].  In another non-
dimorphic system involving spinal cord injury rather than axotomy, increased BDNF, along with 
glial-derived neurotrophic factor (GDNF), in exercised muscles was found to ameliorate the 
atrophy of muscle and motorneurons, and improve pain, in rats with spinal cord injury [42, 43].  
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This retrograde transport provides trophic support, maintaining soma size and dendritic 
arborization.  Recent findings also suggest that BDNF can activate different signal transduction 
cascades which may elicit different cellular responses, depending on the source of the 
neurotrophin.  In the hippocampus, for example, target-derived retrograde BDNF activates 
PI3K/Akt pathway, while other sources activate the MEK/ERK pathway [44].  The PI3K/Akt 
pathway, when activated by BDNF, has been shown to cause an enlargement of post-synaptic 
density protein 95 (PSD-95), a protein associated with the strengthening of synapses [45].  A 
recent review describes that target-derived BDNF activated the PI3/Akt pathway to initiate both 
transcriptional-dependent and independent pathways that promote cell survival [46].  
Conversely, activation of the MEK/ERK pathway by BDNF has been implicated protection 
against the excitotoxic effects of glutamate activity [47, 48].       
It should be noted that the BDNF gene is comprised of eight non-coding exons (I-VIII), 
and one coding exon (IX).  During transcription, all but one non-coding exon are spliced out, and 
the remaining non-coding exon is involved in trafficking the mRNA to various cellular 
compartments (Figure 1) [49, 50].  Thus, within a cell, non-coding exons can dictate the precise 
role that BDNF will play due to differential trafficking.  In some cases, BDNF will be trafficked 
to dendrites and play a role in maintaining dendritic and synaptic structure; in other cases, BDNF 
will be transported to presynaptic terminals and act as an anterograde neurotransmitter [51, 52].  
Several promoters and repressors have been described which help to determine which non-
coding exon will be expressed.  A recent study describes differential expression of the non-
coding exons in various neural and non-neural tissues in both mice and rats [53].  This 
differential expression suggests BDNF localization and function can differ depending on the 




Figure 1, from Aid et al. (2007). Exon/intron structure and alternative transcripts of mouse and 
rat BDNF genes. A: Rat BDNF gene structure as described by Timmusk et al. (1993). Exons are 
shown as boxes and introns are shown as lines. B: The new arrangement of exons and introns of 
mouse and rat BDNF genes as determined by analyzing genomic and mRNA sequence data 
using bioinformatics, 5′ RACE, and RT-PCR. The schematic representation of BDNF transcripts 
in relation to the gene is shown below the gene structure. Protein coding regions are shown as 
solid boxes and untranslated regions are shown as open boxes. Each of the eight 5′ untranslated 
exons is spliced to the common 3′ protein coding exon IX. In addition, transcription can be 
initiated in the intron before the protein coding exon, which results in IXA transcripts containing 
5′ extended coding exon. Each transcription unit may use one of the two alternative 
polyadenylation signals in the 3′ exon (arrows). For exon II, three different transcript variants, 
IIA, IIB, and IIC, are generated as a result of using alternative splice-donor sites in exon II 
(arrows marked A, B, and C) [53]. 
 
BDNF synthesis by skeletal muscle is variable, and the specific mechanisms of regulation 
of expression of the neurotrophin by muscle fibers under normal conditions are unclear.  Some 
studies show that BDNF is present in muscle fibers during development and in adult mice and 
birds [2].  Others report that BDNF is present only in adult muscle fibers, and absent during 
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development [1, 54].  The expression of BDNF by skeletal muscle can be altered by varying 
physical and pathological conditions.  For example, recent findings show that exercise (i.e., 
skeletal muscle contraction) leads to an increase in BDNF mRNA and protein levels in skeletal 
muscle [55-57].  In rats, after 5 days of treadmill exercise, BDNF mRNA was significantly 
increased in the soleus muscle, and not in innervating motorneurons.  Interestingly, there was no 
significant increase in BDNF protein levels in the soleus muscle, but the levels of BDNF mRNA 
were significantly higher.  The presence of mRNA suggests that BDNF is being synthesized by 
muscles, then exported to motorneurons [58].  A subsequent study by the same authors 
demonstrated a differential time course of BDNF and TrkB expression in muscle and spinal cord 
after exercise in rats.  BDNF expression increased in soleus muscles after three days of exercise, 
and began to decrease at day seven.  Conversely, BDNF expression continued to increase at day 
seven in the spinal cord.  These authors also determined whether exercise influenced the 
expression of downstream effectors of BDNF signaling that are involved in synaptic 
maintenance and plasticity, including synapsin I, growth-associated protein 43 (GAP-43) and 
cyclic AMP response element-binding protein (CREB).  All downstream effectors of BDNF-
TrkB signaling were increased in the spinal cord of exercised rats.  In addition, synapsin I was 
initially elevated in the soleus muscle, but declined to control levels after seven days of exercise 
[59].  These results suggest that BDNF was produced by stimulated, contracting skeletal muscles 
and was likely transported retrogradely to innervating motorneurons to affect physiological 
functioning.  In summary, BDNF signaling to responsive cells is complex and multi-directional.  
Motorneurons are supplied with BDNF from several sources.  The neurotrophin is synthesized 
by motorneurons, and is also endocytosed from postsynaptic targets [60].  As described in the 
next section, it is hypothesized that BDNF produced in adult target cells, such as skeletal muscle, 
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acts retrogradely to strengthen and potentiate the presynaptic neuron.  In the case of 
neuromuscular systems, skeletal muscle fibers would therefore provide BDNF to regulate the 
growth and morphological maintenance of innervating motorneurons [61, 62].   
The hypothesis that muscle-synthesized BDNF is transported retrogradely to innervating 
motorneurons requires a detailed discussion of this mechanism.  Motorneurons may be up to one 
meter in length and require specific transport processes to move proteins and other molecules 
efficiently to and from the soma in the ventral horns of the spinal cord.  The terms anterograde 
and retrograde transport refer to neuron-specific systems that allow movement of material from 
cell body to axon and from axon to cell body, respectively.  This is made possible by cytoskeletal 
microtubules which run the length of the axon and serve as tracks for transportation.  Motor 
proteins move along the microtubules with bound cargo including organelles, proteins, and 
vesicles of mRNA [63].  The motor proteins include members of the kinesin and dynein families.  
Kinesins are two-headed, ATP-driven proteins that move along the microtubules in 8 nm steps, 
and are generally associated with anterograde transport [64].  Dynein proteins are massive 
multisubunit complexes that are associated with the protein dynactin, which allows for transport 
of cargo retrogradely along the microtubules [65].  This extensively-studied transport system 
makes it plausible for muscle-synthesized neurotrophic factors, such as BDNF, to retrogradely 
support motorneurons.  Hypothetically, when a motorneuron signals to a muscle fiber to contract, 
the muscle responds by contracting and releasing BDNF.  After being released from the muscle 
cell at the neuromuscular junction (NMJ), BDNF binds to its TrkB receptor on the motorneuron.  
Ligand binding induces dimerization of the receptor, which is then internalized and transported 
retrogradely via the dynein complex proteins to the soma.  Here, the signal transduction cascades 
initialized by BDNF-TrkB complexes leads to differential gene transcription [8, 66-68].  In the 
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motorneuron, it is hypothesized that BDNF acts as a positive feedback signal increasing the size 
and strength of the synapses formed between the motorneurons and the neurons of the motor 
cortex, which initiated the original muscle contraction [58, 60, 69, 70].  This feedback system 
could be disrupted in diseases which affect the size, health, and efficacy of muscle fibers.     
Indeed, BDNF and other neurotrophic factors have been implicated in many 
neuromuscular disease processes.  A loss or reduction of neurotrophic factors isn’t necessarily 
the underlying cause of such disorders, but it could be a downstream effect of atrophy of the 
motor unit.  Of particular interest are motor neuron diseases (MNDs), including amyotrophic 
lateral sclerosis (ALS).  This is because unlike many predictably progressing neuromuscular 
diseases, such as Huntington’s chorea, Duchenne’s muscular dystrophy, or spinal muscular 
atrophy, the onset of ALS and other MNDs cannot always be traced to a malfunction of a protein 
or mutation of a single gene.  Research focused on MNDs has brought to light many different 
environmental, cellular, and genetic factors that can increase susceptibility to pathology.  Among 
these are exposure to heavy metals, excessive glutamate stimulation (excitotoxicity), oxidative 
stress, mitochondrial dysfunction, impaired axonal transport, aggregation of cellular proteins – 
specifically neurofilaments, and deficits in neurotrophic factors [2, 3, 58, 71].  These different 
pathways all lead to the same pathological hallmarks of disease.  Thus, MNDs are diseases 
defined by a common outcome, rather than a common cause.   
  Most forms of ALS, in particular, are characterized by degeneration of motorneurons 
and atrophy of the muscles which they innervate [72, 73].  The neural and muscular pathology 
causes ALS patients to suffer from a loss of motor function that eventually leads to paralysis.  In 
most cases, initial muscle atrophy occurs in the appendages, which causes a loss of function in 
the extremities.  As the disease progresses, the axial muscles are affected.  When axial muscles 
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such as the diaphragm and intercostals muscles fail, the patient can no longer breathe without 
ventilatory support [73-76].  The specific neuronal pathology of such diseases includes an overall 
decrease in the number of motorneurons, as well as somal atrophy and loss of dendritic 
arborization.  Additionally, a loss of synaptic input from descending cortical motor neurons has 
also been observed [74, 77, 78].   
The cellular pathology observed in MNDs is similar to that seen after axotomy or spinal 
cord injury.  This supports the hypothesis that BDNF and other trophic signals from target 
musculature serve to maintain the neuromuscular unit [54, 56].  Muscle-synthesized BDNF may 
act as a positive feedback signal, increasing or maintaining the size and strength of the synapses 
formed between the motorneurons and the neurons of the motor cortex, which initiated the 
original muscle contraction [58, 60, 69, 70].  This feedback system may be directly affected in 
MND patients due, in part, to progressive muscle atrophy.  Atrophied muscles may not release 
BDNF as robustly as healthy muscles do.  In addition, a common component of neuropathy in 
patients with MND or spinal cord injury is disrupted retrograde transport, which would lead to a 
decrease in retrograde transport of muscle-synthesized BDNF.  Disrupting the muscle signal, due 
to muscle atrophy as seen in disease, axotomy, or spinal cord injury, leads to specific, 
measurable markers of pathology in the motorneuron.   
Our laboratory sought to further characterize the muscle source of BDNF, and its role in 
the maintenance of the motor unit.  To address this, we have generated a strain of transgenic 
mice that are missing BDNF specifically in muscle fibers.  The motorneurons of these mice were 





CHAPTER TWO: GENERATION, MAINTENANCE, AND PROCESSING OF 
EXPERIMENTAL TISSUE SAMPLES 
 
Introduction 
To generate experimental transgenic mice missing either one or both of the BDNF alleles 
in skeletal muscle, we used tissue-specific Cre-Lox recombination technology.  This strategy 
takes advantage of the Cre-recombinase enzyme present in the virus bacteriophage P1.  The 
enzyme will recognize and excise genomic DNA that is present between two 34-basepair regions 
– called loxP sites [79].  For our studies, we maintained one line of transgenic mice in which the 
coding region of the BDNF gene was flanked by two loxP sites.  A second line of mice carrying 
the Cre-recombinase gene driven by the human skeletal actin promoter was also maintained.  A 
detailed description of the mating scheme follows in the next section. 
 
Methods 
Animal Husbandry, Breeding, and Genotyping 
All mice were housed in a temperature- and light-controlled room (14-h light, 10-h dark 
cycle; 21-23 ºC), and were provided with Mazuri Rodent Chow and water in excess.  Mice were 
maintained according to NRC Guidelines for the Care and Use of Laboratory Animals.  The 
Institutional Animal Care and Use Committee (IACUC) of Northern Michigan University 
approved all protocols.   











; see Table 1) were obtained from Jackson Laboratories (Bar Harbor, 





).  The second strain possessed an X-linked Cre-recombinase gene under the control 
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).  Mice from each strain 
were bred to produce experimental animals lacking one or both copies of muscle-BDNF, as 
described below. 
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Table 1.  Punnet square for experimental F1 cross.  Female mice expressing Cre recombinase 
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; highlighted in blue) were used as 
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BDNF+/-






; highlighted in 
red) were used for the experimental backcross. 
 
The experimental backcross was used to generate muscle
BDNF-/-
 homozygous knockouts 
and muscle
BDNF+/+ 
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Table 2.  Punnet square for experimental backcross.  Female mice expressing Cre recombinase 
under the control of the human skeletal actin promoter, and loxP sites surrounding one allele of 






) were crossed with male mice expressing loxP sites 











; highlighted in green) were used as muscle
BDNF-/-












The resulting lines of transgenic mice are designated in this thesis as the following:  
1) Muscle 
BDNF +/+




) – Mice possess a functional 
BDNF gene in muscle tissue. 
2) Muscle 
BDNF +/-




) – Mice express 
one allele of BDNF in skeletal muscle. 
3) Muscle 
BDNF -/- 




) – Mice express no 
BDNF in skeletal muscle tissue. 
 
 
 Experimental and control animals were identified using PCR and gel electrophoresis.  
One set of primers used in PCR genotyping was used to verify the presence or absence of the 
loxP sites flanking the BDNF gene.  The second set of primers determined the presence or 





Figure 1.  PCR Genotyping for Floxed BDNF and Cre-recombinase.  (A) Primers were used to 
verify the presence or absence of loxP sites surrounding the BDNF coding exon.  The PCR 
product of floxed alleles are 68 bp longer than the native PCR product.  Animals that have one 
floxed allele and one native allele (BDNF
Lox+/-
) display two bands after electrophoresis (lanes 2, 
4, 5, and 9).  Animals that have both alleles floxed (BDNF
Lox+/+
) display one long band (lanes 3, 
6, 7, and 8).  (B) Primers were used to detect the presence or absence of the Cre-recombinase 
gene.  Because this gene is non-native to mice, another set of primers were used to detect 
MOUSE GENE as a positive control.  Animals expressing Cre recombinase (X
Cre+
Y) display two 
bands (lanes 2, 3, 6, and 9).  Animals negative for Cre-recombinase (X
Cre-
Y) display only the 
positive control band (lanes 4, 5, 7, and 8).  
 
 
To confirm that the Cre/Lox system in experimental transgenic mice knocked out the 
BDNF coding exon from muscles only, we performed PCR on tissue samples using primers that 
recognize genomic sequences upstream and downstream from the loxP sites flanking the BDNF 
coding exon.  In the absence of HSA-Cre recombinase activity in muscle
BDNF+/+ 
controls, the 
PCR amplification product is approximately 2.45 kilobase-pairs (kbp) in length.  If present in the 
muscles of experimental mice, Cre recombinase will remove a portion of the BDNF coding exon 
that is approximately 1.5 kbp in length.  Thus, using the same primers, the PCR product 
amplified from skeletal muscles of muscle
BDNF-/- 
animals is truncated to 950 bp in size.  PCR 
analysis of skeletal muscles from muscle
BDNF+/- 
experimental mice is expected to show both 
A          B 
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banding patterns, as only one allele of the BDNF coding exon is floxed in these animals.  The 
results of this PCR analysis of skeletal muscle and control tissue from experimental and control 
animals yielded expected results.  In Figure 2, results demonstrate that an intact BDNF gene is 
present in quadriceps, kidney, heart, and brain tissue of muscle
BDNF+/+ 
control animals, as well as 
the kidney, heart, and brain tissue of muscle
BDNF-/- 
homozygous knockout animals, indicated by 
the 2.45 kbp PCR product (lanes 2 through 5, and 7 through 9).  In contrast, the quadriceps 
muscle of the same animal yielded a band approximately 950 bp in size (lane 6, asterisk).  This 
banding pattern indicates that Cre recombinase was active only in skeletal muscle, and 







Figure 2.  Cre recombinase activity is limited to the skeletal muscles of experimental mice.  (A) 
Unaltered 2.45 kbp PCR product in quadriceps (lane 2), kidney (lane 3), heart (lane 4), and brain 
(lane 5) tissue of muscle
BDNF+/+ 
control mouse.  (B) Truncated 950 bp PCR product in quadriceps 
(lane 6, asterisk), while unaltered 2.45 kbp band is detected in kidney (lane 7), heart (lane 8), and 
brain (lane 9) tissue of muscle
BDNF-/-
 homozygous knockout animal.  
 
Surgical Procedures and Tissue Processing 
 For histological and immunohistochemical studies, all mice from experimental and 
control genotypes at 30 d and 120 d time points underwent common procedures.  Briefly, seven 
days prior to sacrifice, experimental and control animals received a 9 µL injection of Fluorogold 
(3% Fluorogold, 1% DMSO) into the gastrocnemius muscle under isofluorane anesthesia.  The 
injection into the gastrocnemius consisted of three 3 µL injections into the distal, medial, and 
proximal regions of the muscle.  Following injection, mice received a subcutaneous injection of 
A              B 
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buprenorphine (0.3 mg/kg) for pain relief and were housed in clean single-mouse cages for 
recovery.  Seven days after injection mice were euthanized by sodium pentabarbitol overdose – 
0.4 µL injected intraperitoneally.  Cardiac perfusion was performed with 4% paraformaldehyde.  
The spinal cords of perfused mice were harvested using pressured air and fixed overnight in 4% 
paraformaldehyde at 4 °C.  Following fixation, spinal cords were stored in 30% sucrose in 
phosphate-buffered saline, pH 7.4 (PBS).  The lumbar and cervical regions of the spinal cords 
were cut into 40 µm sections using a cryostat at -20 ºC.  Lumbar sections were used in 
immunohistochemistry assays to determine if mice with missing or reduced muscle-synthesized 
BDNF exhibited differences in dendritic morphology and/or synaptic input.  The cervical spinal 
cord sections were used to estimate motorneuron number and assess cell body morphology using 




CHAPTER THREE:  A LACK OF MUSCLE-BDNF LEADS TO A DECREASE IN THE 
SOMAL AREA OF ASSOCIATED MOTORNEURONS. 
 
Introduction 
 A marker of MNDs such as ALS is the progressive decrease in the number of 
motorneuron cell bodies by necrotic and apoptotic cell death.  The remaining cell bodies begin to 
atrophy, which causes a decrease in soma size.  Cell bodies can be visualized using thionin (Nissl 
stain), which specifically stains ribosomal RNA.  Atrophied motorneurons, likes those of 
subjects affected by MNDs, do not pick up the Nissl stain as readily as healthy motorneurons. 
 We hypothesized that mice with missing or reduced muscle-synthesized BDNF would 
exhibit similar changes in motorneuron number and cell body size.  If skeletal muscle provides 
trophic support to the motor unit via retrograde BDNF signaling, then motorneurons of 
muscle
BDNF+/- 
heterozygous knockouts and muscle
BDNF-/-
 homozygous knockouts should be 
reduced in number, display decreased cell body size, and exhibit lighter Nissl stain.  We 
expected to see more significant signs of pathology in 120 d experimental mice compared to 30 d 

















n=9) experimental and control mice were 
euthanized by a 0.4 mL intraperitoneal injection of sodium pentabarbitol, as described 
previously.   Mice were then perfused with 40 mL ice-cold 0.9% saline, followed by 40 mL ice-
cold 4% paraformaldehyde.  Cervical spinal cords were harvested from perfused mice and post-
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fixed in 4% paraformaldehyde for 2 hours and then impregnated with 30% sucrose in PBS at 4 
ºC.  After three days, they were cryostat sectioned at 40 µm and mounted on gelatin-subbed 
slides.  They were stored at -20 ºC before thionin staining.  
 
Thionin stain 
Slides containing cervical spinal cord sections were immersed in distilled water for 5 
minutes, then transferred to 0.04% thionin in acetate buffer for 15 minutes.  The slides were 
washed twice in distilled water for 3 minutes and then dehydrated in ascending alcohol solutions 
(70%, 70%, 95%, and 100%) for 3 minutes each.  The slides were cleared in Citrisolv for three 
minutes and then coverslipped using Cytoseal.   
 
Microscopic Analysis 
For each animal, 20-30 images containing several thionin-stained motorneuron cell 
bodies were taken at 40X magnification with a bright light microscope (Figure 3).  An average of 
85 total motorneurons were sampled for each animal in each genetic and age group.  Using 
Olympus CellSens software, the area of each motorneuron soma in each image was determined 
by circumscribing a polygon around its perimeter.  The average motorneuron cell body area was 
calculated for each age and genetic group.  Average soma area for each age and genetic group 
was compared by one-way ANOVA and Bonferroni post-test using GraphPad Prism software.  
Data from both age groups were compared using two-way ANOVA and t-tests to compare the 
same genotype at two different ages.  In addition to somal area, staining intensity was visually 




Results and Discussion 
Reduced or absent muscle-synthesized BDNF leads to a significant decrease in cell body 
size in both early (30 d) and mature (120 d) age groups.  Figure 4 provides representative 
photomicrographs from 120 d mice from each genetic group.  Visually, motorneurons from 
Muscle
BDNF+/-  
heterozygous knockouts and Muscle
BDNF-/-
 homozygous knockouts appear smaller, 
more fusiform or crenated, and have a lighter stain when compared to Muscle
BDNF+/+
 control 
animals.  The fusiform and/or crenated appearance observed in these motorneurons is a common 














Figure 4.  Somal atrophy in cervical 
spinal motorneurons.  Representative 
40X magnification photomicrograph 
of thionin Nissl-stained motor 
neurons in the cervical spinal cord 
from 120 d (A) Muscle
BDNF+/+
 
control mouse (B) Muscle
BDNF+/-
 




knockout mouse. Cell body area 
decreases across genetic groups.  






animals (A and B) appear smaller, 
more fusiform, and stain much 
lighter when compared to 
Muscle
BDNF+/+
 controls.  This 
observation was made across all 
animals, at both 30 d and 120 d ages, 
although it was observed more 
intensely at 120 d.  Additionally, 
note the likely vacuolation (indicated 
by the presence of white pockets) in 
the somata of Muscle
BDNF-/-
 




Analysis revealed that at 30 d, Muscle
BDNF+/- 
heterozygous knockout mice had 
significantly reduced soma size when compared to control of the same age (p<0.01; Figure 5A).  
Similarly, the motorneuron soma size of 30 d Muscle
BDNF-/-
 homozygous knockout mice was 
significantly smaller compared to control (p<0.001; Figure 5B).  At 120 d, both Muscle
BDNF+/- 
heterozygous knockouts and Muscle
BDNF-/-
 homozygous knockouts showed a similar decrease in 
cell body size when compared to Muscle
BDNF+/+
 controls of the same age (P<0.001; Figure 5B). 
Two-way ANOVA and t-tests revealed that both age and genetic group significantly 
affect soma size (Figure 6).  In controls, soma size is significantly decreased at 120 d compared 
to 30 d (P<0.05).  However, this decrease is more severe for Muscle
BDNF+/-
 heterozygous 
knockouts (P<0.01), and there is no significant decrease from 30 d to 120 d in Muscle
BDNF-/- 
homozygous knockouts.   
As mentioned previously, it was noted that Muscle
BDNF+/- 
heterozygous knockouts and 
Muscle
BDNF-/-
 homozygous knockouts did display significantly lighter staining, as well as more 
cases of crenated or fusiform motorneuron cell bodies.  
These results indicate that a muscle source of BDNF likely affects the somal morphology 
of innervating motorneurons.  The dependence of somal morphology on a muscle-source BDNF 
may be less important at earlier ages.  For example, while not significantly different from each 
other, the average somal area of motorneurons from 30 d Muscle
BDNF+/-
 heterozygous knockouts 
is noticeably larger than that of Muscle
BDNF-/-
 homozygous knockout mice (Figure 5A).  By 120 





equalized (Figure 5B).  At 30 d, the reduced amount of BDNF protein produced in the muscles in 
Muscle
BDNF+/-
 mice may still provide adequate trophic support to motorneurons compared to the 
absence of muscle-synthesized BDNF by Muscle
BDNF-/- 
mice.  By 120 d, both heterozygous 
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knockout and homozygous knockouts display a similar decrease in size compared to controls, 
indicating that, with age, muscle-synthesized BDNF becomes more critical for trophic support of 
the motor unit.  Indeed, previous behavior data (not shown) demonstrated that behavior deficits 





Figure 5. Somal atrophy in 
spinal motorneurons.  One-
way ANOVA comparing 
soma area of control mice to 
heterozygous knockout mice 
and homozygous knockout 
mice in (A) 30 d old and (B) 
120 d old animals.  (A) 








homozygous knockout mice 





control animals.  (B) Mean 








homozygous knockout mice 
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Figure 6. Two-way ANOVA comparing soma area at for all genetic groups at both 30 d and 120 
d.  Age and genetics both contribute to a progressive decrease in cell body size.  Muscle
BDNF+/+ 
control animals exhibit reduced cell body area at 120 d compared to 30 d (*; p<0.05).  
Muscle
BDNF+/- 
heterozygous knockout animals experience a more sever decrease in cell body size 
at 120 d compared to 30 d (**; p<0.01).   
 
Conclusion 
 These data demonstrate that muscle-synthesized BDNF likely provides trophic support to 
maintain the size and health of motorneurons.  This effect appears to be dose-dependent at an 
early life stage, as the somal size reduction is more drastic in Muscle
BDNF-/-
 homozygous 
knockout mice than in Muscle
BDNF+/-
 heterozygous knockout mice.  At a later age, the reduction 
appears to be similar between these two groups.  We observed crenated and fusiform cell bodies, 
in both knockout groups, resulting in a decrease in somal area.  Future studies should address 
whether reduction in cell body size continues to progress at older ages.  Analysis of motorneuron 
somata could include assessment for the presence of other pathological markers, including 
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ubiquitinated inclusions.  Ubiquitin is used as a tag to mark vesicles containing proteins and 
other cellular material that is to be degraded.  MND patients display a large number of these 
ubiquitinated inclusions in their motorneuron cell bodies.  Additionally, cell body volume should 
be measured using the Imaris analysis software described below, as it would provide a 
measurement in three dimensions, rather than two.  This would give us a more thorough 
description of size difference among cell bodies, and would provide a better image of their 




CHAPTER FOUR: BDNF PROTEIN EXPRESSION IS ALTERED IN MOTORNEURONS OF 
MICE WITH MISSING OR REDUCED MUSCLE-SYNTHESIZED BDNF. 
 
Introduction 
 BDNF that is potentially transported retrogradely from skeletal muscle to motorneurons 
of the spinal cord may have a direct effect on the overall levels of the neurotrophin observed in 
the soma and dendrites.  Additionally, retrograde BDNF signaling from skeletal muscle may 
influence transcription of the neurotrophin in motorneurons.  Studies indicate that BDNF/TrkB 
binding can drive transcription of BDNF itself, along with other downstream targets [80].  We 
hypothesized that BDNF produced by muscles may influence levels of the neurotrophin in the 
motorneuron either by providing an exogenous source or by regulating transcriptional 
mechanisms, or both.  If this hypothesis is true, reducing or eliminating skeletal muscle-BDNF 
should lead to a decrease in BDNF in the motorneuron cell body and dendrites.  This system 
could be affected in patients with MNDs, due to poor signaling from atrophied muscles, 
decreased retrograde transport, or both.  Using immunohistochemistry and laser-scanning 
confocal microscopy, the relative levels of BDNF protein in the motorneuron soma and dendrites 
of our experimental and control animals were assessed at two different ages.  The antibodies 
used in the immunohistochemical assay labeled Fluorogold-labeled motorneuron cell bodies and 
dendrites and BDNF (used for colocalization analysis) as well as VGLUT1, which is a marker 








One week before spinal cord harvest, under isofluorane anesthesia, the left gastrocnemius 
muscle of experimental animals was exposed by making an incision in the skin from Achilles 
tendon to the posterior knee joint.  The gastrocnemius was then injected with 9 µL of the 
retrograde tracing molecule Fluorogold (3% Fluorogold, 1% DMSO, Fluorochrome, Inc., 
Denver, CO) – 3 µL each proximally, medially, and distally.  Seven days after Fluorogold 
injection, mice were euthanized via 0.4 mL injection of sodium pentabarbitol intraperitoneally.  
After euthanasia, mice were perfused with 40 mL 0.9% saline, followed by 40 mL 4% 
paraformaldehyde.  Lumbar spinal cords were harvested from 30 d and 120 d male mice after 
cardiac perfusion and post-fixed in 4% paraformaldehyde for 2 hours and then impregnated with 
30% sucrose in phosphate-buffered saline at 4 ºC.  After three days, they were cryostat sectioned 
at 40 µm and stored in cryoprotectant solution (10% sucrose in phosphate-buffered saline) for 
three days. 
Immunohistochemistry 
  Lumbar spinal cord sections were washed with 1X phosphate-buffered saline, pH 7.4, 
three times for 10 minutes each and then incubated with blocking buffer (10% donkey serum, 
0.2% triton, 0.1% sodium azide, in 1X PBS) at room temperature for one hour.  Sections were 
then incubated with primary antibodies: 0.1% Rabbit polyclonal anti-Fluorogold; 0.2% Sheep 
polyclonal anti-BDNF; and 0.02% Guinea Pig polyclonal anti-VGLUT1 (EMD Millipore, 
Billerica, MA).  Sections were incubated with primary antibodies on a rocking platform for 24 
hours at room temperature then 24 hours at 4 ºC, after which they were washed again with 1X 
phosphate-buffered saline, pH 7.4, three times for 10 minutes each at room temperature.  
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Sections were incubated with secondary antibodies for one hour at room temperature: 1.3% 
AlexaFluor-488-conjugated Donkey anti-Rabbit IgG; 1.3% AlexaFluor-594-conjugated Donkey 
anti-Sheep IgG; and 1.3% AlexaFluor-647-conjugated Donkey anti-Guinea Pig IgG (Jackson 
ImmunoResearch, West Grove, PA).  After secondary antibody incubation, sections were 
washed again with 1X phosphate-buffered saline, pH 7.4, three times for ten minutes each.  The 
spinal cord sections were then mounted on to clean slides using a paintbrush.  The slides were 
coverslipped using ProLong Gold Antifade Reagent (Invitrogen, Grand Island, NY), and stored 
in a light-proof box at 4 ºC.      
Microscopic Analysis 
 Analysis was performed using an Olympus Fluoview confocal microscope (Olympus 
America, Center Valley, PA).  For each scan, the image size was set to 800 x 800 pixels.  
Confocal images were obtained using either x40 or x60 oil immersion objective.  Fluorogold-
labeled motorneuron somata and dendrites were localized using epifluorescent (mercury vapor) 
illumination.  Then we performed laser-scanning optical sectioning of the selected motorneurons.  
For each motorneuron (n = 20 per animal), we obtained 40-60 stacks of optical sections (Z step 
size = 0.54 µm for x40 objective; 0.45 µm for x60 objective).  Each Z-series was composed of 
scans through three separate channels (488, 594, and 647 nm excitation).  Scans at each 
wavelength were performed sequentially, to eliminate bleed-through between individual 
channels.  All slices from each Z-series were compiled and these images were saved.    
The images were imported to Imaris 7.6 program.  The volume of any Fluorogold-labeled 
cell bodies within the image was defined using the Surfaces object.  The automatic Surfaces 
Creation Wizard was used for this step.  A region of interest containing the imaged cell bodies 
was selected, to avoid detection of background fluorescence.  The source channel was set to 
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Channel 1 – AlexaFluor 488, the fluorophore used to label Fluorogold.  Surface area detail level 
was set to 1 µm, which served to smooth out any roughness on the surface that was less than 1 
µm in diameter.  After running the Wizard, background fluorescence and poorly-labeled cell 
bodies were filtered out by filtering for a thresholded number of voxels value.  This filter 
eliminated any surfaces that contained less voxels than the threshold value.  If two or more cell 
bodies were close enough that their surfaces overlapped, these surfaces were cut using the 
Surfaces Toolkit, so that the cell body surface for each neuron was distinct.   
The mean intensity of Channel 2 – AlexaFluor 594, the fluorophore used to label BDNF 
protein – colocalized to these surfaces was measured.  These data were used as a means of 
comparing the amount of BDNF protein in motorneuron cell bodies between age and genetic 
groups.  These data were compared by one-way ANOVA and Bonferroni post-test using 
GraphPad Prism software.  Data from genetic groups at both 30 d and 120 d were analyzed using 
two-way ANOVA and t-tests.         
 
Results and Discussion 
 At 30 d, there is no significant difference in the mean immunofluorescent intensity of 
BDNF in motorneuron cell bodies and dendrites of Muscle
BDNF+/+ 
control animals and 
Muscle
BDNF+/-
 heterozygous knockout mice (Figure 7).  These findings suggest that motorneurons 
of Muscle
BDNF+/-
 experimental mice maintain normal expression of BDNF protein.  In contrast, 
and somewhat surprisingly, BDNF immunofluorescent intensity is significantly increased in 
Muscle
BDNF-/-
 homozygous knockout mice compared with Muscle
BDNF+/+
 controls and 
Muscle
BDNF+/-
 heterozygous knockouts (P<0.001; Figure 7).   
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Production of BDNF protein appears to be drastically increased in 30 d Muscle
BDNF-/-
 
motorneurons as a result of a total absence of the protein synthesized in muscles at this age.  The 
most parsimonious explanation for this increase is a compensatory mechanism – i.e. 
motorneuron synthesis of BDNF is upregulated due to a lack of BDNF signaling from muscles.   
 
Figure 7.  Expression of BDNF in motorneurons of 30 d mice.  One-way ANOVA comparing mean 







 mice.  BDNF is significantly increased in Muscle
BDNF-/-
 mice (***, P<0.001). 
 
In mice at 120 d, expression patterns of BDNF in motorneurons are altered from the 
younger age.  In contrast to 30 d mice, BDNF immunofluorescent intensity in motorneurons of 
120 d Muscle
BDNF+/+
 controls is not different than that of Muscle
BDNF-/-
 homozygous knockout 





heterozygous knockout mice is significantly higher than Muscle
BDNF-/-
 homozygous mice and 
Muscle
BDNF+/+
 control animals (p<0.001; Figure 8).    
         
Figure 8.  Expression of BDNF in motorneurons of 120 d mice.  One way ANOVA comparing BDNF 







mice.  BDNF is significantly increased in Muscle
BDNF+/- 
mice (***, P<0.001). 
 
 Two-way ANOVA and t-tests revealed differences among all genetic groups when 
comparing 30 d to 120 d.  BDNF immunofluorescent intensity was significantly higher in 
Muscle
BDNF+/+ 
control animals at 120 d compared to 30 d (Figure 9; p<0.05).  This suggests that 
BDNF levels in motorneurons naturally increase with age.  The results for Muscle
BDNF+/-
 
heterozygous animals and Muscle
BDNF-/- 
homozygous animals did not trend this way, but BDNF 
levels were significantly different between age groups for both genetic groups (Figure 9; 













































Figure 9.  Two-way ANOVA of BDNF immunofluorescent intensity for all genetic groups at 30 
d and 120 d.  Muscle
BDNF+/+ 
control animals exhibit an increase in BDNF levels at 120 d 
compared to 30 d (P<0.05).  Muscle
BDNF+/- 
heterozygous knockout animals exhibit an increase in 
BDNF levels at 120 d compared to 30 d (P<0.0001).   Muscle
BDNF-/- 
homozygous knockout 
animals exhibit a decrease in BDNF levels at 120 d compared to 30 d (P<0.0001). 
 
The change in expression patterns can be visualized in the representative confocal 
micrographs in Figure 10.  The top panel of Figure 10 (A-C) displays micrographs from 30 d 
animals.  Notice the intense yellow fluorescence (signifying colocalization of green and red 
fluorophores) in motorneurons of Muscle
BDNF-/-
 animals (10C), in comparison to the green 
fluorescence in motorneurons of both Muscle
BDNF+/+ 
control animals (10A) and Muscle
BDNF+/-
 
heterozygous knockout animals (10B).  The bottom panel of Figure 10 (D-F) displays 
representative micrographs from 120 d animals.  At this age, we see intense yellow-labeled 
motorneurons from Muscle
BDNF+/-
 heterozygous knockouts.  In contrast, the motorneurons of 
both Muscle
BDNF-/- 
homozygous knockouts and Muscle
BDNF+/+
 controls appear green, indicative 





Figure 10.  Neuropathological markers in motorneurons.  Representative confocal micrograph of 
lumbar spinal cord sections immunoreactive for Fluorogold (green), BNDF (red)  and VGLUT1 




, and (C) Muscle
BDNF-/-





, and (F) Muscle
BDNF-/- 
mice.  Note the intense yellow 
fluorescence in 8A and 8E – indicative of a high amount of overlap between red and green 
fluorophores.  In 8C and 8F, we see additional examples of a small, crenated cell body, as 
described in Chapter 3.     
 
These results suggest that at a young age (30 d), the reduction of muscle-synthesized 
BDNF in Muscle
BDNF+/-
 mice does not influence BDNF levels in innervating motorneurons, 
which remain at levels of controls at this age.  In contrast, motorneurons of 30 d Muscle
BDNF-/-
 
homozygous knockout mice exhibit a significant increase in BDNF immunofluorescent intensity 
compared to either Muscle
BDNF+/-
 heterozygous knockout mice for Muscle
BDNF+/+
 controls.  At 30 
d, the absence of BDNF produced by skeletal muscle in Muscle
BDNF-/-
 mice seems to induce 
increased production of the neurotrophin by motorneurons, possibly as compensation for a 
reduced retrograde signal from muscles.   
At a more mature age (120 d), the reduction of muscle-synthesized BDNF in 
Muscle
BDNF+/-
 mice does appear to affect motorneuron synthesis of BDNF.  These mice 
experience an increase of motorneuron-localized BDNF similar to that seen in 30 d Muscle
BDNF-/-
 
        D           E                       F
     
        A           B                       C
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animals.  Conversely, the motorneurons of Muscle
BDNF-/-
 homozygous knockout animals display 
levels of BDNF protein near those of Muscle
BDNF+/+
 control mice.  At this later age, it appears 
that any compensatory increase in Muscle
BDNF-/-
 homozygous knockout mice has waned, but that 
Muscle
BDNF+/-
 heterozygous knockout are compensating.      
 
Conclusion  
 From these data it can be concluded that muscle-synthesized BDNF affects expression of 
BDNF in motorneurons.  A reduction or loss of BDNF from skeletal muscle appears to 
upregulate production of BDNF in motorneurons, although this happens at different ages 
depending on the amount of BDNF present in the muscles.  It is possible that upregulation occurs 
in motorneurons once the consequences of muscle-synthesized BDNF loss reach a critical point.  
In homozygous knockouts, this occurs at an early age, due to the absence of BDNF.  Normal 
BDNF levels appear to persist in motorneurons of heterozygous knockout mice for a longer 
period of time, due to the presence of some muscle-synthesized BDNF.   
 To further characterize this potential critical period, transgenic mice should be examined 
at several additional time points.  Homozygous knockouts should be compared to controls and 
heterozygous knockouts at 10 d and 20 d to elucidate whether or not motorneuron levels of 
BDNF ever mimic those of controls, and if so, when the spike in BDNF production occurs.  
Heterozygous knockout mice should be compared to controls and homozygous knockouts 
between 30 d and 120 d (perhaps 60 d and 90 d) to again determine the point at which 
motorneuron levels of BDNF begin to rise.  Determining BDNF expression by motorneurons at 
these ages will also allow us to understand whether the increase in BDNF production occurs 
gradually or spikes acutely.  All mice should be examined beyond 120 d of age, to determine 
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whether BDNF levels eventually return to normal or if they are significantly reduced when 
compared to controls at a later age.   
 It can be hypothesized that in control animals, BDNF signaling from muscles to 
motorneurons helps to maintain a homeostatic level of BDNF expression.  In the absence (at an 
early age) or reduction (at a mature age) of this signal, stress pathways are potentially activated 
that upregulate transcription and translation of BDNF.  Because we see a drop in Muscle
BDNF-/-
 
homozygous knockouts at a later age, it can be assumed that after a period of compensatory 
upregulation, the activity of this pathway is reduced to levels comparable to control animals. 
 The mechanism behind this compensation is unclear.  It is likely that trophic signals from 
intact motor units also feed back to cortical motorneurons.  Because there is a loss of BDNF 
signal from muscle, the feedback to the motor cortex is disrupted.  This may lead to increased 
stimulation of spinal motorneurons by cortical motorneurons.  In cases of axotomy, spinal cord 
injury, or muscle atrophy, where there is a loss of connection between spinal motorneurons and 
their target musculature, an increase in excitatory cortical input is observed.  It is possible that 
increased excitatory input from the cortical motorneurons leads to the compensatory increase in 
BDNF production by the motorneurons.  The next step in addressing this issue would be two 
analyze the motorneurons for BDNF mRNA.  This would elucidate whether the increased BDNF 
is being produced in the spinal motorneurons themselves, or imported from other areas, 
including cortical motorneurons or supporting glial cells.  This could be done using in situ 
hybridization on spinal cord tissue or reverse-transcriptase polymerase chain reaction (RT-PCR).   




CHAPTER FIVE: THE EFFECT OF ABSENT OR REDUCED MUSCLE-SYNTHESIZED 
BDNF ON DENDRITIC LENGTH, DIAMETER, AND SYNAPTIC INPUT. 
Introduction 
 Progression of MNDs results in a loss of the dendritic arborization of the affected 
motorneurons.  This in turn reduces the amount of excitatory synapses that these motorneurons 
receive from cortical areas and brain stem nuclei [81, 82].  We hypothesized that muscle-
synthesized BDNF provides trophic support to innervating motorneurons, maintaining dendritic 
morphology and synapses.  BDNF has been shown to maintain and promote growth of dendrites 
and synapses in several brain areas [6-9], thus, a similar function in the neuromuscular unit can 
be reasonably assumed.  In mice with missing or reduced muscle-synthesized BDNF, a 
progressive decrease in dendritic length and diameter, and a reduction in synaptic input were 
predicted.  We employed immunohistochemical techniques to visualize Fluorogold-labeled 
dendrites and VGLUT1 (a marker of excitatory synapses) to compare these morphological 




The tissue was prepared as described in Chapter Four.  Under isofluorane anesthesia, the 
left gastrocnemius muscle of experimental animals was injected with 9 µL of the retrograde 
tracing molecule Fluorogold (3% Fluorogold, 1% DMSO, Fluorochrome, Inc., Denver, CO) – 3 
µL each proximally, medially, and distally.  Seven days after Fluorogold injection, lumbar spinal 
cords were harvested from 30 d and 120 d male mice after cardiac perfusion and post-fixed in 
4% paraformaldehyde for 2 hours and then impregnated with 30% sucrose in phosphate-buffered 
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saline at 4 ºC.  They were cryostat sectioned at 40 µm and stored in cryoprotectant solution (10% 
sucrose in phosphate-buffered saline) for three days. 
Immunohistochemistry 
The immunocytochemistry was done as described in Chapter Four.  Lumbar spinal cord 
sections were washed with 1X phosphate-buffered saline, pH 7.4, three times for 10 minutes 
each and then incubated with blocking buffer (10% donkey serum, 0.2% triton, 0.1% sodium 
azide, in 1X PBS) at room temperature.  Sections were then incubated with primary antibodies: 
0.1% Rabbit polyclonal anti-Fluorogold; 0.2% Sheep polyclonal anti-BDNF; and 0.02% Guinea 
Pig polyclonal anti-VGLUT1 (EMD Millipore, Billerica, MA).  Sections were incubated with 
primary antibodies for 24 hours at room temperature then 24 hours at 4 ºC, after which they were 
washed again with 1X phosphate-buffered saline, pH 7.4, three times for 10 minutes each at 
room temperature.  Sections were incubated with secondary antibodies for one hour at room 
temperature: 1.3% AlexaFluor-488-conjugated Donkey anti-Rabbit IgG; 1.3% AlexaFluor-594-
conjugated Donkey anti-Sheep IgG; and 1.3% AlexaFluor-647-conjugated Donkey anti-Guinea 
Pig IgG (Jackson ImmunoResearch, West Grove, PA).  After secondary antibody incubation, 
sections were washed again with 1X phosphate-buffered saline, pH 7.4, three times for ten 
minutes each.  They were then mounted on clean slides and coverslipped using ProLong Gold 
Antifade Reagent (Invitrogen, Grand Island, NY).     
Confocal microscopy and image analysis 
Analysis was performed using an Olympus Fluoview confocal microscope (Olympus 
America, Center Valley, PA).  For each scan, the image size was set to 800 x 800 pixels.  
Confocal images were obtained using either x40 or x60 oil immersion objective.  Fluorogold-
labeled motorneuron somata and dendrites were localized using epifluorescent (mercury vapor) 
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illumination.  Then we performed laser-scanning optical sectioning of the selected motorneurons.  
For each motorneuron (n = 20 per animal), we obtained 40-60 stacks of optical sections (Z step 
size = 0.54 µm for x40 objective; 0.45 µm for x60 objective).  Each Z-series was composed of 
scans through three separate channels (488, 594, and 647 nm excitation).  Scans at each 
wavelength were performed sequentially, to eliminate bleed-through between individual 
channels.  All slices from each Z-series were compiled and these images were saved. 
The images were imported to Imaris 7.6 program.  The volume of Fluorogold-labeled cell 
bodies was defined the Surfaces function.  Fluorogold-labeled dendrites were traced using Imaris 
Filament Tracer.  Within the Filament Tracer menu, the semi-automatic “AutoPath” method was 
selected.  This method requires the manual definition of seed points and terminal points of each 
dendritic branch.  The cell bodies of neurons within the images were marked as seed points.    
Once end points were defined, the program automatically computed the path to the seed point.  
After all dendrites were traced, post-modification was done using the Filament Toolkit.  The 
filament style was set to “cone”, which automatically fills the diameter of the dendrite.  The 
range was set to 1 µm to 18 µm (minimum and maximum diameter, respectively). 
The Spots object was used to render synaptic terminals.  The automatic Spots Creation 
Wizard was used for this step.  The source channel was set to Channel 3 – AlexaFluor 647, 
which was the fluorophore used to label VGLUT1.  The estimated XY diameter was set to 1.5 
µm.  After running the Wizard, the threshold was adjusted so that all synapses were detected, but 
no artificial synapses were detected.  Using the MatLab program, we were able to detect and 
enumerate spots (synapses) making appositions on surfaces (cell bodies) and filaments 
(dendrites).  This eliminated spots that were farther than 0.5 µm from surfaces or filaments.  




Figure 11.  Imaris image analysis for dendritic length, diameter, and VGLUT1 synaptic input.  
(A) A confocal micrograph becomes a three dimensional rendering in which soma and dendrites 
are traced and filled to diameter, synapses are defined, and background structures are eliminated.  
(B) All synapses are eliminated except those making appositions on the motorneuron of interest.   
 
For each image, data were collected on dendrite length, dendrite diameter, number of 
synapses apposing dendrites, and number of synapses apposing cell bodies.  The data for 
dendrite length at 30 d were compared by one-way ANOVA and Bonferroni post-test GraphPad 
Prism.  The data for dendrite length at 120 d were abnormally distributed.  Thus, these data were 
compared within each age and genetic group by one-way ANOVA to ensure there was no 
significant difference between animals in each group.  After this was completed, the lengths of 
all dendrites of all animals in a group were pooled, and the distribution of lengths was compared 
using a Kolmogorov-Smirnov (K-S) Test Comparison Plot.  The groups compared using the K-S 
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test are listed in Table 3.  The data for dendrite diameter apposed spots were each compared by 
one-way ANOVA and Bonferroni post-test using GraphPad Prism software.    
Groups Compared in K-S Test 
30 d muscle
BDNF+/+ 
control 30 d muscle
BDNF+/-
 heterozygous knockout 
30 d muscle
BDNF+/+
 control 30 d muscle
BDNF-/-
 homozygous knockout 
120 d muscle
BDNF+/+





 control 120 d muscle
BDNF-/- 
homozygous knockout 
Table 3. Groups compared in Kolmogorov-Smirnov (K-S) Comparison Plot.  Four K-S tests 
were run.  Each row describes the two groups compared with one another in a K-S test.  
 
Results and Discussion 
 The data obtained for average dendritic length across all age and genetic groups were 
statistically compared using the Kolmogorov-Smirnov (K-S) test due to bimodal distribution of 
values in experimental groups, which could not be accurately analyzed by one-way ANOVA.  
The K-S test allowed us to pool the values for all animals in each genetic group and compare the 
distribution of values.  The bimodal distribution was especially observed in the 120 d age group, 
which was analyzed first.  The 30 d age group had a more normal distribution and was analyzed 
by one-way ANOVA.   
At 30 d, there is a striking difference in the in the distribution of dendritic lengths of both 
Muscle
BDNF+/- 
heterozygous knockouts and Muscle
BDNF-/- 
homozygous knockouts, when 
compared with Muscle
BDNF+/+ 
control animals.  One-way ANOVA reveals that Fluorogold-
labeled dendrites of Muscle
BDNF+/-
 heterozygous knockouts and Muscle
BDNF-/-
 homozygous 
knockouts are significantly shorter compared to Muscle
BDNF+/+ 
control animals (Figure 12; 
p<0.0001).  Additionally, Muscle
BDNF-/-
 homozygous knockouts exhibit significantly shorter 
Fluorogold-labeled dendrites compared to Muscle
BDNF+/-
 heterozyougs knockouts (P<0.01).   
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Figure 12.  Decreased motorneuron dendritic length in 30 d mice with missing or reduced muscle- 
synthesized BDNF.  One-way ANOVA comparing the distribution of dendritic length of 30 d 
Muscle
BDNF+/-
 heterozygous knockouts to Muscle
BDNF+/+ 
control animals (P<0.0001); and Muscle
BDNF-/- 
homozygous knockouts to Muscle
BDNF+/+
 control animals (P<0.0001).   
 
 
The K-S test allows us to view the differences between two samples at any given 
cumulative fraction (CF).  At 120 d, the distribution of dendritic lengths is statistically different 
in both Muscle
BDNF+/- 
heterozygous knockouts and Muscle
BDNF-/- 
homozygous knockouts, when 
compared with Muscle
BDNF+/+ 
control animals.  Control mice display a dendritic length around 50 
µm in the 50
th
 percentile (CF = 0.5).  This number is 40 µm for both heterozygous knockouts and 
homozygous knockouts.  The maximum dendritic length (CF = 1.0) for 120 d control animals is 
235 µm for control animals.  This is greatly reduced in experimental groups – 160 µm for 
heterozygous knockouts and 110 µm for homozygous knockouts.  For 120 d heterozygous 
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knockouts compared with controls, D = 0.2432 (P<0.0001; Figure 13A).  For 120 d homozygous 





 For each age group, we see a significant difference in dendritic length when comparing 
experimental mice to control mice.  This difference is far more drastic in 30 d animals than in 
120 d animals.  This may seem counterintuitive, if the prediction of progressive pathology is 
made.  However, if the role of BDNF in development is considered, then it stands to reason that 
reducing or eliminating one source of the protein would have a more severe effect at a younger 
 
Figure 13.  Differential 
motorneuron dendritic length in 
120 d mice with missing or reduced 
muscle-synthesized BDNF.  
Kolmogorov-Smirnov Test 
comparing the distribution of 



















age.  The neuromuscular unit of mice at 30 d of age could rely more heavily on trophic support 
of muscleBDNF than that of mice at 120 d of age, when development of the nervous system is 
complete.  The comparison of dendrite length between control mice at 30 d and 120 d supports 
the idea that dendrites are still undergoing development at this stage.  We see a linear distribution 
of dendrite lengths at 30 d, with a maximum length of 200 µm.  At 120 d, we observe a more 
normal distribution of lengths, with a maximum length of 250 µm.  Because of this difference, 
we can assume that the dendrites of 30 d mice are still undergoing development at this age.   
 These data specifically illustrate that there is a difference between the amount of 
Fluorogold labeling in motorneuron dendrites.  The question arises whether this is due to a 
decrease in dendritic length, disrupted retrograde transport, or both.  As mentioned previously, 
Fluorogold is a molecule that relies on the retrograde axonal transport system to fill, and 
therefore label, somata and dendrites of innervating motorneurons.  Thus, the differences we 
observe initially suggest that dendrites are shorter in experimental animals, but they could also 
result from the inability of the motorneuron to transport Fluorogold retrogradely.  This 
distinction needs to be made clear in further studies.  Immunohistochemistry could be performed 
on the spinal cords of muscle-BDNF knockout mice for microtubule-associated protein 2 
(MAP2) – a protein that is involved in microtubule assembly and enriched in dendrites.  This 
technique would not rely on retrograde transport, and would thus be a more definitive measure of 
dendritic length differences.  This cannot be concluded without further research, but it is 
probable that the observed effects are due to a disruption in retrograde transport, based on the 
observed dendritic lengths.  The average length of lumbar motorneuron dendrites of adult mice 
about 2000 µm [83].  Our data find the maximum value at 250 µm, even in adult control mice.  
Thus, the dendrites are not being completely filled by the Fluorogold in the control nor the 
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experimental animals.  It can be assumed, then, that the transport of the Fluorogold retrogradely 
is less efficient in mice with missing or reduced muscleBDNF.   
One-way ANOVA reveals that, at 30 d, the mean diameter of Fluorogold-labeled 
dendrites are significantly decreased in Muscle
BDNF-/-
 homozygous knockouts compared to 
Muscle
BDNF+/+
 controls (P<0.01; Figure 14).  There is no significant difference in dendritic 
diameter comparing Muscle
BDNF+/+ 
control animals to Muscle
BDNF+/-
 heterozygous knockout 
animals.     
Dendritic Diameter in Lumbar

























Figure 14.  Dendritic diameter in motorneurons of 30 d mice.  The mean diameter of Fluorogold-
labeled dendrites is significantly decreased in Muscle
BDNF-/- 





heterozygous knockout mice (**; P<0.01). 
 
One-way ANOVA reveals that, at 120 d, the mean diameter of Fluorogold-labeled 
dendrites are significantly decreased in both Muscle
BDNF+/-
 heterozygous knockouts and 
Muscle
BDNF-/-
 homozygous knockouts compared to Muscle
BDNF+/+
 controls (P<0.001; Figure 15).   
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Figure 15.  Reduced dendritic diameter in mice with missing or reduced muscle-synthesized 
BDNF.  There is a significant decrease in both Muscle
BDNF+/-
 heterozygous knockout animals and 
Muscle
BDNF-/-
 homozygous knockout animals compared to Muscle
BDNF+/+
 control animals (***; 
P<0.001). 
 
 The reduction we observe in dendritic diameter in both heterozygous knockout mice and 
homozygous knockout mice does not hold the same uncertainty as the dendritic length 
measurements.  These differences cannot be attributed to disrupted retrograde transport, and thus 
are a strong indicator of atrophy of the dendritic arborization in mice with missing or reduced 
muscle-synthesized BDNF.  In other neuronal networks, it has been well-characterized that 
target-derived BDNF activates the PI3K/Akt pathway to promote growth of dendrites and 
strengthen synapses.  Our results suggest a similar mechanism in neuromuscular systems.  It 
appears that without this target-derived source of BDNF, dendrites begin to atrophy. 
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 The differences in the length of Fluorogold-labeled dendrites can be seen in Figure 16, 
which shows representative confocal micrographs from each age and genetic group.   
 
 
Figure 16.  Neuropathological markers in motorneurons.  Confocal micrograph of lumbar spinal 
cord sections immunoreactive for Fluorogold (green), BNDF (red)  and VGLUT1 (magenta) in 
30 d (A) Muscle
BDNF+/+ 
control animals, (B) Muscle
BDNF+/-
 heterozygous knockouts, and (C) 
Muscle
BDNF-/-
 homozygous knockouts; and 120 d (D) Muscle
BDNF+/+ 
control animals, (E) 
Muscle
BDNF+/-
 heterozygous knockouts, and (F) Muscle
BDNF-/-
 homozygous knockouts.  Note the 
reduced length and diameter in knockout animals (B, C, E, F). 
 
 For each confocal micrograph, the dendritic synapses were enumerated, as well as the 
somal synapses.  These numbers were highly variable.  The total number of synapses for each 
neuron (dendritic appositions + somal appositions) was then compared by one-way ANOVA.    
There was no significant difference in the amount of VGLUT1-positive appositions among 
genetic groups at 120 d (Figure 17) or 30 d (not shown).     
        A           B                       C
     
        D           E                       F




Figure 17. Mean number of VGLUT1 immunofluorescent appositions on Fluorogold labeled 
lumbar motoneurons.  There was no significant difference in VGLUT1-positive contacts on 











The data collected via the Spots Object in Imaris 7.6 were highly variable.  The values for 
number of synapses on a neuron ranged from 0 to 207.  These results are not sufficient to 
conclude that there is actually not a difference in the synapses of mice with missing or reduced 
BDNF.  The variability (and the fact that it is highly improbable that any neuron would have 0 
synapses) suggests an error in the methodology.  One parsimonious explanation is that the 
motorneurons, and more specifically their dendritic arbors, become caught, stretched, and/or 
displaced during cryostat sectioning.  If this is the case, then simply labeling the postsynapse, 
rather than the presynapse, for postsynaptic density protein 95 (PSD-95) or NMDA receptors 







 From the present data, it may be concluded that muscle-synthesized BDNF acts 
retrogradely to provide trophic support to motorneurons and our data demonstrate that muscle-
synthesized BDNF may help to maintain the retrograde axonal transport system.  This could be 
achieved through the action of BDNF itself – for example, BDNF could act retrogradely to 
directly upregulate transcription of proteins involved in retrograde transport.  Conversely, it may 
be indirectly affecting retrograde transport.  Current studies in our laboratory report distinct 
pathology in the muscle fibers of Muscle
BDNF+/- 
heterozygous knockout and Muscle
BDNF-/-
 
homozygous knockout mice.  This pathology includes atrophy and hypertrophy of muscle fibers, 
fiber splitting, and centralized nuclei.  Thus, healthy muscles might provide the motorneuron 
with some other diffusible factor that maintains the retrograde transport system – a factor that is 
not present or is ineffective in the degenerated muscle fibers of the muscle-BDNF knockouts.  It 
is also possible that the retrograde transport system is not, in fact, disrupted.  Instead, it could be 
that the dendrites actually are shorter in Muscle
BDNF+/-
 heterozygous knockouts and Muscle
BDNF-/-
 
homozygous than in Muscle
BDNF+/+
 controls.  This explanation is less plausible than the former, 
as the largest dendrite measured in our analyses was about 250 µm in length, while the average 
motorneuron dendrite measures 2000 µm in length.  The data collected for dendrite diameter do, 
in fact, indicate dendritic atrophy in both heterozygous knockout mice and homozygous 
knockout mice.  As described in the Discussion section of this chapter, a different approach to 
labeling dendrites and synapses should be taken to get a better idea of differences in dendritic 




CHAPTER SIX: SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 The present studies lay the groundwork for much more research concerning the role of 
muscle-synthesized BDNF in the health and maintenance of neuromuscular systems.  Through 
our tissue-specific knockouts, we have presented evidence that muscle-synthesized BDNF 
provide trophic support retrogradely to innervating motorneurons. 
In Chapter Three, we showed that muscle-synthesized BDNF directly affects the size of 
innervating cell bodies.  We showed that eliminating or reducing muscle-BDNF leads to a 
decrease in cell body area, and that this effect is dose-dependent at an early life stage (30 d).  The 
reduction appears not to be dose-dependent at a late life stage (120 d).  Future studies should 
examine cell body size at more life stages – e.g. 10 d, 20 d, 60 d, 90 d, 150 d, and 210 d.  It may 
also be useful to measure cell body volume using the Imaris Surfaces Object to analyze the three-
dimensional confocal micrographs. 
Chapter Four provides evidence that muscle-synthesized BDNF affects the production of 
itself in motorneuron cell bodies.  This effect could be due to direct regulation by BDNF, or 
more likely due to other signals within the neuromuscular unit.  Interestingly, we see an 
upregulation of motorneuron-synthesized BDNF as a result of reducing or eliminating muscle-
synthesized BDNF at varying life stages depending upon whether muscle-synthesized BDNF is 
reduced or eliminated.  This increase appears to be a compensatory response to stress, as it 
happens early for homozygous knockouts, and late for heterozygous knockouts.  Thus, it is most 
likely not BDNF which directly regulates itself retrogradely in the motorneuron, but perhaps 
other signals that are released due to neuromuscular stress.  With limited data, we conclude that 
there is a probable increase in BDNF production in the motorneuron at a critical time.  The same 
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type of data needs to be collected from mice at more age groups (suggested above) to fully 
observe how muscle-BDNF affects the production of motorneuron-BDNF.             
The objective of Chapter Five was to understand how muscle-synthesized BDNF affects 
the dendritic arborization and synaptic input of innervating motorneurons.  Although we were 
unable to demonstrate this conclusively through our analysis of dendritic length and VGLUT1 
labeling, it is likely that muscle-synthesized BDNF does, in fact, maintain dendrites and 
synapses.  We did see changes in dendritic diameter in our knockout mice at both age groups, 
which cannot be attributed to disrupted retrograde transport.  In light of these changes in 
diameter, and our conclusions about trophic support of the somata in Chapter Three and research 
performed to address BDNF’s role in the synaptic signaling in the brain.  Therefore, these 
objectives should be pursued as described in the Conclusion section of Chapter Five.  For 
example, dendrites should be labeled with a dendrite specific antibody, such as MAP2.  This 
method does not rely on retrograde transport, and so would allow us to definitively compare the 
length and diameter of dendrites across genetic and age groups. Synapses should be labeled with 
PSD-95, which would eliminate the possibility that dendrites are displaced away from their 
excitatory synapse during cryostat sectioning.   
  Chapter Five provides evidence that retrograde transport is disrupted in mice with 
missing or reduced muscle-BDNF.  We observed a reduction in the length of Fluorogold-labeled 
dendrites in both heterozygous and homozygous muscle-BDNF knockouts.  Because the tracing 
molecule Fluorogold relies on the retrograde transport system, and because our measured lengths 
are much shorter than the average lumbar spinal cord motorneuron dendritic length, we can 
reasonably assume that the differences may be due to disrupted transport.  This transport system 
may be regulated by BDNF directly, or it may be that other transcription factors responsible for 
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the maintenance of this system are negatively affected by unhealthy muscle fibers and 
motorneurons. 
We can conclude that the muscle source of BDNF is integral to the maintenance of the 
neuromuscular unit, although the exact mechanisms by which it does this remain unknown.  A 
reduction or loss of this protein from skeletal muscle leads to several cellular markers also 
present in neuromuscular diseases.  This trophic support system from muscles may be disrupted 
or affected in a multitude of human neuromuscular diseases in which muscle fibers are atrophied.  
Any retrograde trophic signal from muscle will be reduced when fibers are atrophied.  Moreover, 
these results mimic results seen in models of spinal cord injury and axotomy, were the 
connection between motorneurons and target musculature is disrupted.  This provides evidence 
that BDNF is one of the important diffusible factors that is affected in these models.  In addition 
to the further experimentation described above, research should be proposed and performed to 
fully understand role of BDNF produced in the muscle.  This includes a complete analysis of 
muscle fiber pathology at all life stages, an analysis of the neuromuscular junction, and 
characterization of behavioral pathology in muscle-BDNF knockout mice.  If this pathology 
matches or mimics that of neuromuscular diseases, then exogenous BDNF applied at the 
neuromuscular junction could be considered as a viable treatment option for such diseases.  
Further, the mechanism by which muscle-synthesized BDNF supports and maintains the motor 
unit should be described.  Future studies should examine the gene transcription pathways 
activated by muscle-synthesized BDNF/TrkB binding.  Again, it is uncertain whether some of 
the effects we see are directly related to BDNF/TrkB signaling, or if they are the result of a loss 
of other signaling molecules due to atrophied muscle fibers and motorneurons.  Thus, the 
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